- Treffer 1 von 1
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-203704
- Published experience with carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) and extramedullary disease (EMD) is still limited. The current study aimed to assess the efficacy and safety of carfilzomib containing therapy regimens in EMD. We retrospectively analyzed 45 patients with extramedullary RRMM treated with carfilzomib from June 2013 to September 2019. The median age at the start of carfilzomib was 64 (range 40–80) years. Twenty (44%) and 25 (56%) patients had paraosseous manifestation and EMD without adjacency toPublished experience with carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) and extramedullary disease (EMD) is still limited. The current study aimed to assess the efficacy and safety of carfilzomib containing therapy regimens in EMD. We retrospectively analyzed 45 patients with extramedullary RRMM treated with carfilzomib from June 2013 to September 2019. The median age at the start of carfilzomib was 64 (range 40–80) years. Twenty (44%) and 25 (56%) patients had paraosseous manifestation and EMD without adjacency to bone, respectively. The serological overall response rate (ORR) was 59%. Extramedullary response was evaluable in 33 patients, nine (27%) of them achieved partial remission (PR) (ORR = 27%). In 15 (33%) patients, we observed no extramedullary response despite serological response. The median progression-free survival (PFS) and overall survival (OS) were five (95% CI, 3.5–6.5) and ten (95% CI, 7.5–12.5) months, respectively. EMD without adjacency to bone was associated with a significantly inferior PFS (p = 0.004) and OS (p = 0.04) compared to paraosseous lesions. Carfilzomib based treatment strategies showed some efficacy in heavily pretreated patients with extramedullary RRMM but could not overcome the negative prognostic value of EMD. Due to the discrepancy between serological and extramedullary response, evaluation of extramedullary response using imaging is mandatory in these patients.…
Autor(en): | Xiang Zhou, Patricia Flüchter, Katharina Nickel, Katharina Meckel, Janin Messerschmidt, David Böckle, Sebastian Knorz, Maximilian Johannes Steinhardt, Franziska Krummenast, Sophia Danhof, Hermann Einsele, K. Martin Kortüm, Leo Rasche |
---|---|
URN: | urn:nbn:de:bvb:20-opus-203704 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Medizinische Fakultät / Medizinische Klinik und Poliklinik II |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | Cancers |
ISSN: | 2072-6694 |
Erscheinungsjahr: | 2020 |
Band / Jahrgang: | 12 |
Heft / Ausgabe: | 4 |
Aufsatznummer: | 1035 |
Originalveröffentlichung / Quelle: | Cancers (2020) 12:4, 1035. https://doi.org/10.3390/cancers12041035 |
DOI: | https://doi.org/10.3390/cancers12041035 |
Sonstige beteiligte Institutionen: | Mildred Scheel Early Career Center |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Freie Schlagwort(e): | carfilzomib; extramedullary disease; multiple myeloma; refractory; relapse |
Datum der Freischaltung: | 07.06.2022 |
Datum der Erstveröffentlichung: | 23.04.2020 |
Lizenz (Deutsch): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |